A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG

Summary

This observational trial is designed to investigate long-term survival with regard to the primary endpoint overall survival (OS) after start of first-line treatment.

Eligibility

Inclusion Criteria:

* • Subjects must voluntarily sign and date an informed consent, ap-proved by an independent ethics committee (IEC)/institutional review board (IRB)

  * Documented diagnosis of CLL at time point of inclusion in a first-line study of the GCLLSG (development of RT is not an exclusion criterion)
  * First-line treatment was administered within one of these first-line studies of the GCLLSG (CLL13, CLL14, or CLL17).
  * Subsequent therapy lines were either documented during the participa-tion in a first-line study of the GCLLSG or patient consented to have the subsequent therapy lines documented within this observational trial.
  * Subjects are willing and able to comply with procedures required in this protocol.

Exclusion Criteria:

* • Patients without participation in one of the first-line studies of the GCLLSG (CLL13, CLL14, CLL17)

  * Subjects with legal incapacity
  * Subjects who are institutionalized by regulatory or court order
  * Subjects who are in dependence to the sponsor or the investigator

Conditions2

Browse More Trials